| scholarly article | Q13442814 |
| P50 | author | James R. Williams | Q50696148 |
| P2093 | author name string | Melissa Gerstenhaber | |
| Kevin Biglan | |||
| Laura Marsh | |||
| P2860 | cites work | Training of executive functions in Parkinson's disease. | Q52015436 |
| Reduction of noradrenaline impairs attention and dopamine depletion slows responses in Parkinson's disease. | Q52531979 | ||
| A case of mania associated with tomoxetine. | Q53732162 | ||
| Functional assessment staging (FAST) | Q57306313 | ||
| The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients | Q69903875 | ||
| A rating scale for depression | Q24564540 | ||
| “Mini-mental state” | Q25938989 | ||
| Parkinsonism: onset, progression, and mortality | Q28259134 | ||
| Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases | Q29614910 | ||
| The Clinical Dementia Rating (CDR): current version and scoring rules | Q29616280 | ||
| Cardiovascular effects of atomoxetine in children, adolescents, and adults | Q35178553 | ||
| Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease | Q36227392 | ||
| Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. | Q36834550 | ||
| Quality of life in patients with Parkinson's disease: development of a questionnaire | Q36894428 | ||
| Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder | Q38462707 | ||
| The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia | Q39605807 | ||
| Cognitive deficits in Parkinson's disease | Q41328582 | ||
| Neurochemical modulation of response inhibition and probabilistic learning in humans | Q42794222 | ||
| Methylphenidate increases the motor effects of L-Dopa in Parkinson's disease: a pilot study | Q43692038 | ||
| Prodromal frontal/executive dysfunction predicts incident dementia in Parkinson's disease. | Q43785660 | ||
| Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies | Q44290885 | ||
| Pramipexole in comparison to l-dopa: a neuropsychological study | Q44377180 | ||
| Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study | Q46193667 | ||
| Efficacy and safety of donepezil in the treatment of executive dysfunction in Parkinson disease: a pilot study | Q46630471 | ||
| Atomoxetine and stroop task performance in adult attention-deficit/hyperactivity disorder | Q46725710 | ||
| Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine | Q46757968 | ||
| Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder | Q48099054 | ||
| Defining mild cognitive impairment in Parkinson's disease | Q48212869 | ||
| Reaction time and vigilance in Parkinson's disease. Possible role of altered norepinephrine metabolism | Q48619580 | ||
| Similar effects of the selective noradrenaline reuptake inhibitor atomoxetine on three distinct forms of impulsivity in the rat. | Q51980642 | ||
| ??? | Q64900482 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| atomoxetine | Q417240 | ||
| executive disfunction | Q5419936 | ||
| P304 | page(s) | 277-282 | |
| P577 | publication date | 2009-01-01 | |
| P1433 | published in | Movement Disorders | Q1486418 |
| P1476 | title | Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study | |
| P478 | volume | 24 |
| Q92582730 | A Randomized Clinical Trial of Atomoxetine for Mild Cognitive Impairment in Parkinson's Disease |
| Q37862761 | A précis of recent advances in the neuropsychology of mild cognitive impairment(s) in Parkinson's disease and a proposal of preliminary research criteria |
| Q34293012 | A review of executive function deficits and pharmacological management in children and adolescents. |
| Q38156172 | Acute and chronic cognitive effects of levodopa and dopamine agonists on patients with Parkinson's disease: a review |
| Q38571668 | Advances in the treatment of cognitive impairment in Parkinson's disease |
| Q35867093 | Age-related neurodegeneration and memory loss in down syndrome |
| Q41662403 | Assessing frontal behavioral syndromes and cognitive functions in traumatic brain injury |
| Q90641261 | Atomoxetine Does Not Improve Complex Attention in Idiopathic Parkinson's Disease Patients with Cognitive Deficits: A Meta-Analysis |
| Q36870256 | Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's Disease |
| Q33647691 | Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease |
| Q38848619 | Atomoxetine restores the response inhibition network in Parkinson's disease |
| Q48642615 | Clinical trials of dementia with Lewy bodies and Parkinson's disease dementia |
| Q41540738 | Cognitive Function in Parkinson's Disease Patients with and without Anxiety |
| Q38206496 | Cognitive deficits in Parkinson's disease: a cognitive neuroscience perspective |
| Q34307633 | Cognitive dysfunction and depression in Parkinson's disease: what can be learned from rodent models? |
| Q22251235 | Cognitive enhancers for the treatment of ADHD |
| Q37364568 | Cognitive impairment in Parkinson's disease: the dual syndrome hypothesis |
| Q37968511 | Cognitive impairment in nondemented Parkinson's disease |
| Q47765302 | Comparative Patient Satisfaction and Feasibility of a Pilot Parkinson's Disease Enrichment Program. |
| Q41993777 | Connectivity analysis is essential to understand neurological disorders |
| Q37798797 | Dopamine Receptor Agonists for the Treatment of Early or Advanced Parkinsonʼs Disease |
| Q35119408 | Dopaminergic modulation of motor network dynamics in Parkinson's disease |
| Q38067142 | Drug treatments for the neuropsychiatric complications of Parkinson's disease |
| Q38875190 | Dysfunctional Sensory Modalities, Locus Coeruleus, and Basal Forebrain: Early Determinants that Promote Neuropathogenesis of Cognitive and Memory Decline and Alzheimer's Disease |
| Q49438954 | Effects of dopaminergic drug adjustment on executive function in different clinical stages of Parkinson's disease |
| Q30492753 | Impaired verbal memory in Parkinson disease: relationship to prefrontal dysfunction and somatosensory discrimination |
| Q35264006 | Improving response inhibition in Parkinson's disease with atomoxetine |
| Q38225930 | Latest treatment options for Alzheimer's disease, Parkinson's disease dementia and dementia with Lewy bodies |
| Q33965475 | Longitudinal changes in task-evoked brain responses in Parkinson's disease patients with and without mild cognitive impairment |
| Q35165280 | Monoamine reuptake inhibitors in Parkinson's disease |
| Q30611520 | Neuroimaging of brain changes associated with cognitive impairment in Parkinson's disease |
| Q38799051 | Neuropsychiatric Issues in Parkinson's Disease |
| Q37794466 | Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease |
| Q47837913 | Neurotransmitter deficits from frontotemporal lobar degeneration |
| Q36244162 | New onset executive function difficulties at menopause: a possible role for lisdexamfetamine |
| Q37825377 | Nonmotor disturbances in Parkinson's disease |
| Q55004525 | Noradrenergic Dysfunction in Alzheimer's and Parkinson's Diseases-An Overview of Imaging Studies. |
| Q38258228 | Norepinephrine deficiency in Parkinson's disease: the case for noradrenergic enhancement |
| Q41975512 | Norepinephrine: the next therapeutics frontier for Parkinson's disease |
| Q64240263 | Novel Treatment Opportunities Against Cognitive Impairment in Parkinson's Disease with an Emphasis on Diabetes-Related Pathways |
| Q38258699 | Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease |
| Q34618993 | Off-label use of atomoxetine in adults: is it safe? |
| Q31080551 | Orthostatic hypotension and cognitive impairment in Parkinson's disease: Causation or association? |
| Q36186763 | Parkinson's disease dementia: a neural networks perspective |
| Q38929226 | Pilot study of atomoxetine in patients with Parkinson's disease and dopa-unresponsive Freezing of Gait |
| Q39072339 | Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. |
| Q48514539 | Preliminary validation of the Spanish version of the Frontal Systems Behavior Scale (FrSBe) using Rasch analysis |
| Q37250382 | Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease |
| Q33906753 | Reduced noradrenergic innervation of ventral midbrain dopaminergic cell groups and the subthalamic nucleus in MPTP-treated parkinsonian monkeys |
| Q37779808 | Safinamide in the treatment of Parkinson's disease |
| Q33784038 | Targeting impulsivity in Parkinson's disease using atomoxetine |
| Q36998284 | Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease. |
| Q38394430 | The effect of desvenlafaxine on cognitive functioning in employed outpatients with major depressive disorder: a substudy of a randomized, double-blind, placebo-controlled trial. |
| Q42248817 | The emerging role of norepinephrine in cognitive dysfunctions of Parkinson's disease |
| Q26799352 | The impact of neuroscience on society: cognitive enhancement in neuropsychiatric disorders and in healthy people |
| Q33724698 | The neurobiological basis of cognitive impairment in Parkinson's disease |
| Q48821094 | Treatment of Apathy in Huntington's Disease and Other Movement Disorders |
| Q34388686 | Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease |
| Q30358337 | Treatment of psychosis and dementia in Parkinson's disease. |
| Q27021220 | Mild cognitive impairment in Parkinson's disease. |
Search more.